Search
Flecainide
go.drugbank.com/drugs/DB01195ApprovedInvestigationalWithdrawn[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.[L8875] … [A186880] Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics.
Products: Nra-flecainideAgalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigational[A220343] Agalsidase beta was granted FDA approval on 24 April 2003.[L16383] … While patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.
Eldecalcitol
go.drugbank.com/drugs/DB05295InvestigationalEldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. … Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.
Categories: Vitamin D and AnaloguesTiratricol
go.drugbank.com/drugs/DB03604ApprovedInvestigationalTiratricol is an analogue and active metabolite of the thyroid hormone triiodothyronine (T3). … treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized by chronic tissue thyrotoxicosis and abnormal neuronal development due
Silodosin
go.drugbank.com/drugs/DB06207ApprovedInvestigational[A231159] Silodosin was first approved by the FDA in October 2008 [A231159] and it is also approved in Europe and Canada.
Motixafortide
go.drugbank.com/drugs/DB14939ApprovedInvestigational[A261476] Motixafortide was approved by the FDA in September 2023, in combination with filgrastim, for use in stem cell mobilization prior to autologous stem cell transplant in patients with multiple … is commonly employed in the context of hematologic cancers - high-dose chemotherapy regimens destroy cancerous blood cells, which are then replaced via infusion of the patient's own stem cells (i.e. an
Istisociclib
go.drugbank.com/drugs/DB21703InvestigationalIstisociclib has a monoisotopic molecular weight of 287.21 Da. … Istisociclib is under investigation in clinical trial NCT04718675 (A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer
Sodium cellulose phosphate
go.drugbank.com/drugs/DB06776Approved[A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption.
Arginine
go.drugbank.com/drugs/DB00125ApprovedInvestigationalNutraceuticalAn essential amino acid that is physiologically active in the L-form.
Mixtures: SOLUCION DP-AMINE, TRAVASOL PLUS 15% LIBRE DE BISULFITO